All In MedTech

Device Trial Radar · NCT06162195

The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2036

Sponsor

Lead sponsor
Embody Orthopaedic LimitedNot on our public-company list
Sponsor type
Industry
Collaborators
Imperial College London; National Institute for Health Research, United Kingdom
First posted
Dec 8, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomised controlled trial is to compare the success of two types of hip replacement in patients with hip arthritis. The main question it aims to answer is whether a new type of hip replacement (called a hip resurfacing) can be as successful as an existing hip replacement (called a total hip replacement). Patients will be given either the new hip resurfacing or the existing total hip replacement and researchers will compare their function, complication rate and physical activity.

Conditions

  • Osteoarthritis, Hip
  • Inflammatory Arthritis

Interventions

  • The H1 ImplantDevice

    Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.

  • Cementless total hip replacementDevice

    Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite clinical success (CCS)Time frame: 24 months post-operatively

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Dorset NHS Foundation Trust

    Bournemouth, United Kingdom · Recruiting

  • University Hospitals Coventry & Warwickshire

    Coventry, United Kingdom · Recruiting

  • Royal Cornwall Hospitals NHS Trust

    Truro, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.